HexemBio

📍 New York, United States🗓 Founded 2024👥 11 employees💰 Last funded Jul 2025
Biotechnology Research🌐 hexemb.io
Website LinkedIn
HexemBio is developing regenerative therapies based on the Synthetic Human Yolk Sac, a technology designed to rejuvenate aging blood stem cells by recreating the developmental environment where they first arise. By restoring the regenerative capacity of a patients own hematopoietic stem cells, HexemBio aims to improve outcomes in bone marrow transplantation and unlock new approaches to extending human healthspan. The company received FDA Orphan Drug Designation in July 2025 and completed its FDA Pre-IND meeting in January 2026. Founded in 2024, HexemBio operates from New York City and from Berkeley. To learn more, visit hexemb.io.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2024
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
United Kingdom
1
Frequently asked questions
Who invested in HexemBio?
HexemBio has 2 investors on record on gritt.io, including 2 early-stage backers.
When did HexemBio last raise funding?
The most recent investment in HexemBio recorded on gritt.io was in July 2025.
When was HexemBio founded?
HexemBio was founded in 2024.
What industry is HexemBio in?
HexemBio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is HexemBio based?
HexemBio is headquartered in New York, United States.